Akeso
Akeso, Inc. is a Chinese biopharmaceutical enterprise that discovers, develops, manufactures, and commercializes innovative antibody therapeutics for oncology and autoimmune diseases. The company operates through an integrated biopharmaceutical research and commercialization model, utilizing its proprietary TETRABODY drug discovery platform. Its principal revenue drivers consist of commercial sales of proprietary bispecific and monoclonal antibody drugs, upfront licensing payments, and milestone royalties from global pharmaceutical partners. Akeso holds a prominent market position in China's biopharmaceutical sector as a pioneer in bispecific antibody treatments, having commercialized breakthrough immuno-oncology drugs including cadonilimab and ivonescimab. The enterprise focuses on developing next-generation bispecific antibodies, executing global clinical trials, advancing commercial manufacturing capacity, and establishing international commercial partnerships. Akeso, Inc. is headquartered in Zhongshan, Guangdong Province, China, and its common shares are publicly listed and traded on the Hong Kong Stock Exchange.
17 of the funds FundTelligence covers report a position in Akeso.
- Legal name
- Akeso Inc
- Sector
- Health Care
- Country
- China
- Funds holding it
- 17
Funds holding Akeso
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.09 % (full portfolio disclosed, December 2025)
- Lannebo Emerging Markets — Lannebo · 0.07 % (full portfolio disclosed, June 2026)
- Handelsbanken Asia Tema — Handelsbanken · 0.07 % (full portfolio disclosed, August 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.06 % (full portfolio disclosed, October 2026)
- DNB Emerging Markets Index — DNB · 0.06 % (full portfolio disclosed, September 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.05 % (full portfolio disclosed, June 2026)
- Storebrand Emerging Markets — Storebrand · 0.05 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 17 funds holding it.